MH

Martin Heidecker

Chief Investment Officer at AMR Action Fund

Cambridge, Massachusetts

Overview

Work Experience

AA

AMR Action Fund

  • Chief Investment Officer

    2021 - Current

  • Member Board of Directors AMR action

    2020 - 2021

M

MassBio

  • Board Member MassBio Biotechnology

    2020

LT

Libra Therapeutics

  • Member Board of Directors Libra Therapeutics Inc.

    2020 - 2021

Tiga Therapeutics Inc.

  • Member Board of Directors Tiga Tx Inc.

    2020 - 2021

RT

Rgenta Therapeutics Inc.

  • Member Board of Directors Rgenta Therapeutics Inc.

    2020 - 2021

AB

Abexxa Biologics, Inc.

  • Member Board of Directors Abexxa Biologics Inc.

    2016 - 2021

Sentien Biotechnologies, Inc.

  • Member Board of Directors

    2015 - 2021

Boehringer Ingelheim Venture Fund USA Inc.

  • Managing Director BIVF USA Inc.

    2013 - 2021

    Run Boehringer Ingelheim Venture Fund offices in the United States, scout for early investment opportunities in Cambridge and other sites of innovation and lead respective Due Diligence, invest in start-up biotech companies and represent BIVF US as a Board Director.

AT

ArmaGen Technologies

  • Member Board of Directors

    2012 - 2020

121 Bio LLC

  • Member Board of Directors

    2014 - 2016

Education

Investments

Vedanta Biosciences

Series E

Total Funding: $110M

BioVersys

Series C

Total Funding: $9M

Venatorx Pharmaceuticals

Series C

Total Funding: $76M

Adaptive Phage Therapeutics

Series B

Total Funding: $61M

Relevant Websites